|
Action :
-
CLINACYN
inhibits bacterial
protein synthesis by binding to 50S subunit of bacterial
ribosome , so
inhibits the early stage of protein
synthesis , especially in the cell wall .
-
CLINACYN
may reduce microbial adherence and enhance phagocytosis
.
-
Clinacyn
is active against wide
Varity of pathogenic including :
(Ι)
Aerobic gram (+ve) Cocci
(Π)
Anaerobic gram (+ve) bacilli
(ΙΠ)
Anaerobic gram (-ve) bacilli
(V) Protozoa
Indications :
CLINACYN treats :
Bone and joints infected with
staphylococci e.g. osteomylitis
Dental infections due to susceptible
organisms .
Liver abscesses .
Aerobic and anaerobic infections e.g. :
Cellulitis .
Abscesses - furunculosis and anaerobic
infections of ulcers .
Actinomycosis .
Diabetic foot
burns
Pelvic, tubular and ovarian abscesses .
Endometritis .
Bacterial vaginosis .
Anaerobic infections e.g. :
Pneumonia .
Empyemia .
Lung abscesses
Aerobic infections e.g. :
Pharyngitis due to streptococcal
infections ( usually treats carrier state ) .
Carrier state of Diphtheria .
Dose :
Adults :
In adult 150 – 300 mg/ 6–12 hours from
moderate to severe infections .
In severe infections : 450 mg/ 6-8 hours
.
Children :
8 – 20 mg/Kg/day in 6 hourly divided dose
. |
